University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Albert J. Chang, M.D., Ph.D.

Radiation cancer specialist

Dr. Albert Chang is a radiation oncologist who specializes in radiation therapy for genitourinary, gastrointestinal and gynecologic cancers. He has expertise in radiation techniques such as stereotactic body radiotherapy, Cyberknife radiosurgery, brachytherapy and intensity modulated radiation therapy.

Chang earned a Ph.D. in molecular medicine and a medical degree at Boston University School of Medicine in 2007. He completed a residency in radiation oncology at Washington University School of Medicine. In research, his interests are in the development of molecular imaging probes and targeted therapies. He has developed imaging agents that characterize tumors at the cellular level. These imaging agents have the potential to be used to define disease extent, predict treatment response and optimize therapy. He is also involved in the design of clinical trials to study advanced imaging, radiation therapy and targeted drug therapies to maximize the therapeutic effect and minimize side effects. He is an assistant professor of radiation oncology at UCSF.


Pancreas Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Patient Information and Appointments: (415) 353-9888
Administrative Inquiries: (415) 353-7390
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. — 5 p.m.

Radiation Oncology at Mount Zion
1600 Divisadero St., Basement Level
San Francisco, CA 94143-1708
Main Phone: (415) 353-7175
New Patient Appointments: (415) 353-9807
Fax: (415) 353-9884

Hours: Monday to Friday
7 a.m. – 6 p.m.

Conditions & Treatments

More about Albert J. Chang


Boston University School of Medicine 2007


Washington University Medical Center 2012

Selected Research and Publications

  1. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M, Chang AJ, Chan JM, Simko JP, Carroll PR. Patterns of Local Failure following Radiation Therapy for Prostate Cancer. J Urol. 2015 Oct; 194(4):977-82.
  2. Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M, Hsu IC, Gottschalk AR. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015 Sep-Oct; 5(5):e465-72.
  3. Raleigh DR, Hsu IC, Braunstein S, Chang AJ, Simko JP, Roach M. Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy. Brachytherapy. 2015 Mar-Apr; 14(2):185-8.
  4. Chang AJ. Editorial comment. Urology. 2014 Dec; 84(6):1387-8.
  5. Chang AJ, Autio KA, Roach M, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014 Jun; 11(6):308-23.
  6. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014; 9:42.
  7. Beaino W, Guo Y, Chang AJ, Anderson CJ. Roles of Atox1 and p53 in the trafficking of copper-64 to tumor cell nuclei: implications for cancer therapy. J Biol Inorg Chem. 2014 Mar; 19(3):427-38.
  8. Nedrow JR, White AG, Modi J, Nguyen K, Chang AJ, Anderson CJ. Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate. Mol Imaging. 2014; 13.
  9. Chang AJ, Sohn R, Lu ZH, Arbeit JM, Lapi SE. Detection of rapalog-mediated therapeutic response in renal cancer xenografts using 64Cu-bevacizumab immunoPET. PLoS One. 2013; 8(3):e58949.
  10. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 1; 86(2):324-9.
  11. Chang AJ, Roach M. Cautious optimism for extreme dose escalation in prostate cancer. Eur Urol. 2013 Dec; 64(6):939-40.
  12. Chang AJ, De Silva RA, Lapi SE. Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. Mol Imaging. 2013 Jan-Feb; 12(1):17-27.
  13. Gay HA, Jin JY, Chang AJ, Ten Haken RK. Utility of normal tissue-to-tumor a/ ratio when evaluating isodoses of isoeffective radiation therapy treatment plans. Int J Radiat Oncol Biol Phys. 2013 Jan 1; 85(1):e81-7.
  14. Chang AJ, Roach M. Radium-223: down to the bone, and less is more. Oncology (Williston Park). 2012 Apr; 26(4):342, 344.
  15. Chang AJ, Desilva R, Jain S, Lears K, Rogers B, Lapi S. 89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors. Pharmaceuticals (Basel). 2012; 5(1):79-93.
  16. Chang AJ, Zhao H, Wahab SH, Moore K, Taylor M, Zoberi I, Powell SN, Klein EE. Video surface image guidance for external beam partial breast irradiation. Pract Radiat Oncol. 2012 Apr-Jun; 2(2):97-105.
  17. Chang AJ, Dehdashti F, Bradley JD. The role of positron emission tomography for non-small cell lung cancer. Pract Radiat Oncol. 2011 Oct-Dec; 1(4):282-8.
  18. Chang AJ, Richardson S, Grigsby PW, Schwarz JK. Split-field helical tomotherapy with or without chemotherapy for definitive treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1):263-9.
  19. Chang AJ, Bradley JD. Clinical perspectives on dose escalation for non-small-cell lung cancer. Clin Lung Cancer. 2010 Sep 1; 11(5):299-302.
  20. Chang AJ, Song DH, Wolfe MM. Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation. J Biol Chem. 2006 May 26; 281(21):14700-10.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.